Physician profile
Michael A Brickman
NPI 1528284700
$1,335.80
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $202 · 2021: $389 · 2022: $197.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $247.18 | 2019-2022 | |
| Integra Lifesciences Corporation | $175.62 | 2019-2021 | |
| Merz North America, INC. | $149.80 | 2019-2022 | |
| Sientra, INC. | $140.29 | 2021-2022 | |
| Ethicon US, LLC | $116.46 | 2021 | |
| Novo Nordisk INC | $97.76 | 2019 | |
| Tei Biosciences INC | $87.87 | 2019 | |
| Polynovo North America LLC | $59.64 | 2021 | |
| Tela Bio, INC. | $56.73 | 2019 | |
| Allergan, INC. | $34.17 | 2019-2022 | |
| Davol INC. | $25.20 | 2020 | |
| Mentor Worldwide LLC | $24.98 | 2019 | |
| Derma Sciences, INC. | $21.86 | 2019 | |
| Galderma Laboratories, L.P. | $19.51 | 2021 | |
| Acera Surgical, INC. | $18.24 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tepha INC | $16.62 | 2019 | |
| Apyx Medical Corporation | $15.43 | 2019 | |
| Arthrosurface Incorporated | $14.84 | 2019 | |
| Medartis INC. | $13.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.